Insilico Medicine

Insilico Medicine reported rising revenue stemming from deals with AI firms. Alex Zhavoronkov, Founder & CEO of the firm, discussed the company's earnings and business outlook. This discussion took place exclusively on "Bloomberg: The China Show."

Insilico Medicine, a biotech firm, leverages Abu Dhabi's AI computing resources to develop a non-opioid painkiller candidate, its second from the UAE facility. The drug, nearing human trials, could revolutionize pain treatment and is part of Abu Dhabi's broader strategy to attract biotech innovation through investments and infrastructure.

Insilico Medicine and SK Biopharmaceuticals signed a $2.5B partnership to develop neuroimmune therapies using AI-driven drug discovery. Insilico will design candidates via its Pharma.AI platform, while SK Biopharmaceuticals handles late-stage development and commercialization. The deal includes potential milestone payments and royalties, marking Insilico's largest Asia-Pacific collaboration.

Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage advancements in AI and the growing $5.3 trillion global longevity market driven by aging populations.

Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage the growing global longevity market, valued at $5.3 trillion.